FR3001729B1 - Mutants du facteur x - Google Patents

Mutants du facteur x

Info

Publication number
FR3001729B1
FR3001729B1 FR1350930A FR1350930A FR3001729B1 FR 3001729 B1 FR3001729 B1 FR 3001729B1 FR 1350930 A FR1350930 A FR 1350930A FR 1350930 A FR1350930 A FR 1350930A FR 3001729 B1 FR3001729 B1 FR 3001729B1
Authority
FR
France
Prior art keywords
sequence
amino acids
mutation
seq
sequence seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1350930A
Other languages
English (en)
French (fr)
Other versions
FR3001729A1 (fr
Inventor
Jean Luc Plantier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB SA
Original Assignee
LFB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1350930A priority Critical patent/FR3001729B1/fr
Application filed by LFB SA filed Critical LFB SA
Priority to MX2015009867A priority patent/MX2015009867A/es
Priority to JP2015555777A priority patent/JP2016506945A/ja
Priority to EP14708609.4A priority patent/EP2951297B1/fr
Priority to AU2014210986A priority patent/AU2014210986A1/en
Priority to KR1020157024083A priority patent/KR101942619B1/ko
Priority to DK14708609.4T priority patent/DK2951297T3/en
Priority to US14/765,073 priority patent/US10364424B2/en
Priority to PCT/FR2014/050191 priority patent/WO2014118481A1/fr
Priority to ES14708609.4T priority patent/ES2636162T3/es
Priority to CN201480007229.6A priority patent/CN104995297B/zh
Priority to CA2900010A priority patent/CA2900010A1/en
Publication of FR3001729A1 publication Critical patent/FR3001729A1/fr
Application granted granted Critical
Publication of FR3001729B1 publication Critical patent/FR3001729B1/fr
Priority to IL239889A priority patent/IL239889A0/en
Priority to JP2018213037A priority patent/JP2019050819A/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
FR1350930A 2013-02-04 2013-02-04 Mutants du facteur x Expired - Fee Related FR3001729B1 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
FR1350930A FR3001729B1 (fr) 2013-02-04 2013-02-04 Mutants du facteur x
CN201480007229.6A CN104995297B (zh) 2013-02-04 2014-02-03 因子x突变体
EP14708609.4A EP2951297B1 (fr) 2013-02-04 2014-02-03 Mutants du facteur x
AU2014210986A AU2014210986A1 (en) 2013-02-04 2014-02-03 Factor X mutants
KR1020157024083A KR101942619B1 (ko) 2013-02-04 2014-02-03 인자 ｘ 돌연변이체
DK14708609.4T DK2951297T3 (en) 2013-02-04 2014-02-03 FACTOR X-MUTANTS
US14/765,073 US10364424B2 (en) 2013-02-04 2014-02-03 Factor X mutants
PCT/FR2014/050191 WO2014118481A1 (fr) 2013-02-04 2014-02-03 Mutants du facteur x
MX2015009867A MX2015009867A (es) 2013-02-04 2014-02-03 Mutantes del factor x.
JP2015555777A JP2016506945A (ja) 2013-02-04 2014-02-03 第ｘ因子変異体
CA2900010A CA2900010A1 (en) 2013-02-04 2014-02-03 Factor x mutants
ES14708609.4T ES2636162T3 (es) 2013-02-04 2014-02-03 Mutantes del factor X
IL239889A IL239889A0 (en) 2013-02-04 2015-07-09 Factor x mutations
JP2018213037A JP2019050819A (ja) 2013-02-04 2018-11-13 第ｘ因子変異体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1350930A FR3001729B1 (fr) 2013-02-04 2013-02-04 Mutants du facteur x

Publications (2)

Publication Number Publication Date
FR3001729A1 FR3001729A1 (fr) 2014-08-08
FR3001729B1 true FR3001729B1 (fr) 2015-03-06

Family

ID=48083383

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1350930A Expired - Fee Related FR3001729B1 (fr) 2013-02-04 2013-02-04 Mutants du facteur x

Country Status (13)

Country Link
US (1) US10364424B2 (OSRAM)
EP (1) EP2951297B1 (OSRAM)
JP (2) JP2016506945A (OSRAM)
KR (1) KR101942619B1 (OSRAM)
CN (1) CN104995297B (OSRAM)
AU (1) AU2014210986A1 (OSRAM)
CA (1) CA2900010A1 (OSRAM)
DK (1) DK2951297T3 (OSRAM)
ES (1) ES2636162T3 (OSRAM)
FR (1) FR3001729B1 (OSRAM)
IL (1) IL239889A0 (OSRAM)
MX (1) MX2015009867A (OSRAM)
WO (1) WO2014118481A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3001729B1 (fr) * 2013-02-04 2015-03-06 Lab Francais Du Fractionnement Mutants du facteur x
FR3050992A1 (fr) * 2016-05-06 2017-11-10 Lab Francais Du Fractionnement Mutants du facteur x
EP4299585A3 (en) * 2016-05-13 2024-04-17 The Scripps Research Institute Compositions and methods for anti-thrombotic and hemostatic therapies
FR3077296A1 (fr) * 2018-02-01 2019-08-02 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Dimeres de variants du facteur x

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
US5821088A (en) * 1990-05-11 1998-10-13 Siga Pharmaceuticals, Inc. Use of gram-positive bacteria to express recombinant proteins
AT405516B (de) * 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT410216B (de) * 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
FR2831170B1 (fr) * 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) * 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
JP2007506416A (ja) * 2003-09-26 2007-03-22 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 合成ヘパラナーゼ分子及びその使用
DK1781782T3 (da) * 2004-08-17 2010-08-23 Csl Behring Gmbh Modificerede vitamin K-afhængige polypeptider
EP1728798A1 (en) * 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
MX336958B (es) * 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (en) * 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
US9567382B2 (en) * 2008-04-15 2017-02-14 Genzyme Corporation Methods to produce rod-derived cone viability factor (RdCVF)
KR20110114587A (ko) * 2008-12-19 2011-10-19 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 세린 프로테아제 유도체 및 혈액응고 장애의 치료 또는 예방의 용도
FR3001729B1 (fr) * 2013-02-04 2015-03-06 Lab Francais Du Fractionnement Mutants du facteur x

Also Published As

Publication number Publication date
CA2900010A1 (en) 2014-08-07
ES2636162T3 (es) 2017-10-05
KR101942619B1 (ko) 2019-01-25
AU2014210986A1 (en) 2015-07-23
WO2014118481A1 (fr) 2014-08-07
IL239889A0 (en) 2015-08-31
EP2951297A1 (fr) 2015-12-09
CN104995297A (zh) 2015-10-21
CN104995297B (zh) 2018-10-26
JP2019050819A (ja) 2019-04-04
EP2951297B1 (fr) 2017-05-03
DK2951297T3 (en) 2017-08-28
US20160145598A1 (en) 2016-05-26
MX2015009867A (es) 2015-10-05
FR3001729A1 (fr) 2014-08-08
JP2016506945A (ja) 2016-03-07
US10364424B2 (en) 2019-07-30
KR20150113205A (ko) 2015-10-07

Similar Documents

Publication Publication Date Title
EA201890355A1 (ru) Новые способы индукции иммунного ответа
MX2021003475A (es) Metodos de purificacion de proteinas.
NZ737046A (en) Anti-cgrp antibody formulation
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
FR3041505B1 (fr) Composition acide comprenant au moins une phycocyanine stable a ph acide
MA44322A (fr) Compositions comprenant des souches bactériennes
MA42471B1 (fr) Compositions comprenant des souches bactériennes
NZ747665A (en) Cd200 mutant and its uses
PE20191614A1 (es) Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo
MY192481A (en) Factor viii chimeric proteins and uses thereof
EA201500802A1 (ru) Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы
PE20061040A1 (es) Anticuerpos antiamiloides humanizados
WO2017025179A8 (en) A transglutamine tag for efficient site-specific bioconjugation
CY1122569T1 (el) Πρωτεϊνη δεσμευσης rgma και χρηση αυτης
MX360085B (es) Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso.
WO2017006052A3 (fr) UTILISATION DE FRAGMENTS Fc MODIFIÉS EN IMMUNOTHÉRAPIE
PH12013500715A1 (en) Anticancer fusion protein
GB0711424D0 (en) Recombinant transferrin mutants
EP4374913A3 (en) Novel human serum albumin mutant
FR3001729B1 (fr) Mutants du facteur x
MA45172B1 (fr) Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées
NZ751983A (en) Identification of mutations in channelopsin variants having improved light sensitivity and methods of use thereof
PE20230343A1 (es) Peptidos que estimulan respuestas inmunitarias antitumorales
EP4450078A3 (en) Novel polynucleotides encoding a human fkrp protein
MX2020013158A (es) Proteina cas9 modificada y uso de la misma.

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

ST Notification of lapse

Effective date: 20211005